According to our Transwell migration assay, it is assumed that T cells expressing TNFSF4 in the TME of GBM might induce NK cell migration into the tumor, resulting in a better therapeutic effect of our AKC treatment. The gene discussed is TNFSF4; the disease is glioblastoma.